MIT spin­out aims to im­prove man­u­fac­tur­ing of pep­tides 

Amide Tech­nolo­gies is now mar­ket­ing its pep­tide man­u­fac­tur­ing tech­nol­o­gy at a time when pep­tide-based ther­a­pies such as No­vo Nordisk’s We­govy and Eli Lil­ly’s Moun­jaro are in high de­mand.

The Cam­bridge, MA start­up, which was spun out of the Mass­a­chu­setts In­sti­tute of Tech­nol­o­gy in 2016, de­vel­oped a tech­nol­o­gy that more quick­ly syn­the­sizes long chains of amino acids in­to pep­tides.

CEO Mark Si­mon said in an in­ter­view with End­points News that Amide’s tech could help ease the sup­ply crunch for GLP-1 drugs be­cause the com­pa­ny man­u­fac­tures pep­tides faster than tra­di­tion­al meth­ods. Lil­ly and No­vo have both re­port­ed sev­er­al man­u­fac­tur­ing road­blocks try­ing to meet the de­mand for their GLP-1 drugs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER